The antiviral infusion was just revived as an early treatment for COVID patients. But the drug is relatively expensive and hard to administer, relegating it to what some are calling "stopgap" status.
The medicine is one of the few to win regulatory approval as a treatment for the disease, but has fallen out of favor with the health authority.
The trial studied the efficacy of bamlanivimab in combination with the antiviral remdesivir on hospitalized COVID-19 patients. Researchers concluded the antibody treatment was "unlikely to help."
The drug remdesivir emerged in part because researchers had previously tested it in China through a project whose grant was abruptly ended by the National Institutes of Health.
President Trump is on day two of a planned 5-day course of remdesivir. The medication, approved for treating COVID-19, works by making it harder for the coronavirus to replicate within the body.
One thing that has improved a lot over the course of the pandemic is treatment of seriously ill COVID-19 patients in intensive care units. Here's one man's success story.
The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?
A five-day course of the antiviral drug remdesivir will cost private health insurers in the United States more than $3,000, Gilead Chairman & CEO...
A second shipment of the antiviral drug remdesivir is heading to 29 Navicent, Northside, Piedmont and WellStar hospitals, the state health department...
Though not approved by the Food and Drug Administration, the Georgia Department of Public Health is distributing the antiviral medication remdesivir to...